Palatin (PTN)

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Company profile

Carl Spana
Fiscal year end
Former names
RhoMed Incorporated ...
IRS number

PTN stock data

Investment data

Data from SEC filings
Securities sold
Number of investors


15 May 22
9 Aug 22
30 Jun 23
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Jun 21 Jun 20 Jun 19 Jun 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 37.72M 37.72M 37.72M 37.72M 37.72M 37.72M
Cash burn (monthly) 3.2M 2.58M 2.61M 3.1M 3.16M 2.56M
Cash used (since last report) 13.78M 11.09M 11.22M 13.34M 13.62M 11.03M
Cash remaining 23.94M 26.63M 26.5M 24.38M 24.1M 26.69M
Runway (months of cash) 7.5 10.3 10.2 7.9 7.6 10.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
24 Jun 22 Spana Carl Common Stock Grant Acquire A No No 0 43,528 0 10,526,458
24 Jun 22 Spana Carl Stock Option Common Stock Grant Acquire A No No 0.55 215,625 118.59K 215,625
24 Jun 22 Spana Carl Stock Option Common Stock Grant Acquire A No No 0.55 575,000 316.25K 575,000
24 Jun 22 Wills Stephen T Common Stock Grant Acquire A No No 0 40,659 0 9,360,658
24 Jun 22 Wills Stephen T Stock Option Common Stock Grant Acquire A No No 0.55 186,375 102.51K 186,375
24 Jun 22 Wills Stephen T Stock Option Common Stock Grant Acquire A No No 0.55 497,000 273.35K 497,000
22 Jun 22 Hull Joseph Stanley Common Stock Grant Acquire A No No 0 73,000 0 980,967
22 Jun 22 Hull Joseph Stanley Stock Option Common Stock Grant Acquire A No No 0 128,000 0 128,000
22 Jun 22 Dunton Alan W Common Stock Grant Acquire A No No 0 73,000 0 991,519
22 Jun 22 Dunton Alan W Stock Option Common Stock Grant Acquire A No No 0 128,000 0 128,000
7.8% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 68 67 +1.5%
Opened positions 8 7 +14.3%
Closed positions 7 10 -30.0%
Increased positions 9 8 +12.5%
Reduced positions 11 20 -45.0%
13F shares Current Prev Q Change
Total value 9.86M 9.45M +4.4%
Total shares 18.14M 18.21M -0.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Vanguard 9.56M $4.4M +0.5%
BLK Blackrock 3.1M $1.43M +0.1%
Geode Capital Management 1.69M $778K +1.4%
STT State Street 757.46K $349K +8.2%
Bridgeway Capital Management 683.1K $314K 0.0%
NTRS Northern Trust 427.73K $196K 0.0%
USB U.S. Bancorp. 156.74K $72K 0.0%
Commonwealth Equity Services 119.75K $55K 0.0%
James Investment Research 113.78K $52K 0.0%
GWM Advisors 113.78K $52K 0.0%
Largest transactions Shares Bought/sold Change
WINTON 0 -371.13K EXIT
Millennium Management 90.78K +90.78K NEW
Citadel Advisors 67.44K +67.44K NEW
STT State Street 757.46K +57.44K +8.2%
Qube Research & Technologies 0 -57.16K EXIT
Charles Schwab Investment Management 0 -56.9K EXIT
Connective Portfolio Management 50K +50K NEW
Vanguard 9.56M +48.81K +0.5%
Renaissance Technologies 46.5K +46.5K NEW
Susquehanna International 94.21K +35.57K +60.6%

Financial report summary

  • We have a history of substantial net losses, including a net loss of $33.6 million for the year ended June 30, 2021, and expect to incur substantial net losses over the next few years, and we may never achieve or maintain profitability.
  • We will need additional funding, including funding to complete clinical trials for our product candidates other than Vyleesi, which may not be available on acceptable terms, if at all.
  • We have a limited operating history upon which to base an investment decision.
  • We have limited authorized shares available to raise additional capital through public or private equity offerings, which limits our ability to raise additional capital.
  • Raising additional capital may cause dilution to existing shareholders, restrict our operations, or require us to relinquish rights.
  • The commercial success of Vyleesi for HSDD is a component of our corporate strategy, but we and our licensees may never successfully commercialize Vyleesi for HSDD or obtain approvals in countries other than the United States.
  • Production and supply of Vyleesi depend on contract manufacturers over whom we do not have any control, and there may not be adequate supplies of Vyleesi.
  • Our product candidates other than Vyleesi, including PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis, are still in the early stages of development and remain subject to clinical testing and regulatory approval. If we are unable to successfully develop and test our product candidates, we will not be successful.
  • If clinical trials for our product candidates are prolonged or delayed, we may be unable to commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product sales.
  • We may not be able to secure and maintain relationships with research institutions and other organizations to conduct our clinical trials.
  • Even if our product candidates receive regulatory approval, they may never achieve market acceptance, in which case our business, financial condition and results of operation will be materially adversely affected.
  • Even if our product candidates receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States.
  • If side effects emerge that can be linked to Vyleesi or any of our product candidates (either while they are in development or after they are approved and on the market), we may be required to perform lengthy additional clinical trials, change the labeling of any such products, or withdraw such products from the market, any of which would hinder or preclude our ability to generate revenues.
  • We may not be able to keep up with the rapid technological change in the biotechnology and pharmaceutical industries, which could make any future approved products obsolete and reduce our revenue.
  • Competing products and technologies may make our proposed products noncompetitive.
  • We rely on third parties over whom we have no control to conduct preclinical studies, clinical trials and other research for our product candidates and their failure to timely perform their obligations could significantly harm our product development.
  • Production and supply of our product candidates depend on contract manufacturers over whom we have no control, with the risk that we may not have adequate supplies of our product candidates or products.
  • If we are unable to establish sales and marketing capabilities within our organization or enter into and maintain agreements with third parties to market and sell Vyleesi and our product candidates, we may be unable to generate product revenue.
  • We need to hire additional employees in order to commercialize Vyleesi and our product candidates in the future. Any inability to manage future growth could harm our ability to commercialize Vyleesi and ultimately our product candidates, increase our costs and adversely impact our ability to compete effectively.
  • Our ability to achieve revenues from the sale of our products will depend, in part, on our ability to obtain adequate reimbursement from private insurers and other healthcare payers.
  • Even if we receive regulatory approval for our products in Europe, we may not be able to secure adequate pricing and reimbursement in Europe for us or any strategic partner to achieve profitability.
  • We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.
  • Our internal computer systems, or those of our third-party contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.
  • We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • We are highly dependent on our management team, senior staff professionals and third-party contractors and consultants, and the loss of their services could materially adversely affect our business.
  • Existing coverage for Vyleesi for the treatment of HSDD is classified as a Tier 3 drug by third-party payers, so that demand for Vyleesi is tied to discretionary spending levels of our targeted patient population and particularly affected by unfavorable economic conditions.
  • Both before and after marketing approval, our product candidates are subject to ongoing regulatory requirements and, if we fail to comply with these continuing requirements, we could be subject to a variety of sanctions and the sale of any approved commercial products could be suspended.
  • The regulatory approval process is lengthy, expensive and uncertain, and may prevent us from obtaining the approvals that we require.
  • The FDA has required that two postmarketing studies and a clinical trial be conducted on Vyleesi.
  • Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of any future product candidates and to produce, market and distribute our products after clearance or approval is obtained.
  • Changes in healthcare policy could adversely affect our business.
  • If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish.
  • We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time consuming.
  • If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed.
  • Our patent applications and the enforcement or defense of our issued patents may be impacted by the application of or changes in U.S. and foreign standards.
  • We may not be able to protect our intellectual property rights throughout the world.
  • If we are unable to keep our trade secrets confidential, our technologies and other proprietary information may be used by others to compete against us.
  • Our stock price is volatile and may fluctuate in a way that is disproportionate to our operating performance and we expect it to remain volatile, which could limit investors’ ability to sell stock at a profit.
  • As a public company in the United States, we are subject to the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”). We can provide no assurance that we will, at all times, in the future be able to report that our internal controls over financial reporting are effective.
  • If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.
  • Holders of our preferred stock may have interests different from our common stockholders.
  • Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains.
  • Anti-takeover provisions of Delaware law and our charter documents may make potential acquisitions more difficult and could result in the entrenchment of management.
  • We are a smaller reporting company and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
  • As of September 24, 2021 there were 39,896,902 shares of common stock underlying outstanding convertible preferred stock, options, restricted stock units and warrants. Stockholders may experience dilution from the conversion of preferred stock, exercise of outstanding options and warrants and vesting and delivery of restricted stock units.
  • Our failure to meet the continued listing requirements of the NYSE American could result in a de-listing of our common stock.

Content analysis

H.S. sophomore Avg
New words: abandon, accurately, adjourn, adjournment, beneficially, Cayman, conflict, conversion, costly, deducting, deteriorating, deterioration, disrupt, disruption, dissolution, dividing, energy, entitled, European, exemption, export, favorable, fee, geopolitical, holder, instability, involuntary, Israel, issuable, manner, matter, Medison, military, nationally, par, percentage, placement, Pontifax, preferred, purpose, ratio, redeem, redeemable, redeemed, redemption, rely, Russia, Secretary, set, split, stockholder, thereof, Ukraine, uncertainty, undesignated, Union, volatility, voluntary, vote, voted, voting
Removed: evaluating